Astrazeneca plc Accounts Payable

Astrazeneca plc (AZN) currently reports a accounts payable of $25B as of December 2025. That compares with $22B in the prior-year period — up 12.5% year over year. Use the charts on this page to explore Astrazeneca plc's accounts payable history and peer comparisons.

Astrazeneca plc's accounts payable increased from $22B to $25B — a 12.5% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Astrazeneca plc reported $25B in accounts payable as of December 2025. That compares with $22B in the prior-year period — up 12.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $25B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Astrazeneca plc, and consider following AZN for alerts when major investors trade the stock.

Astrazeneca plc is classified in the Healthcare sector. On accounts payable, it currently shows $25B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AZN with unrelated industries.